{"title":"PET/CT 在提高尼莫妥珠单抗治疗鼻咽癌的成本效益方面的作用。","authors":"Xiao-Bin Fu, Ting-Ting Li, Zhao-Dong Fei, Chuan-Ben Chen","doi":"10.14639/0392-100X-N2827","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study aims to use the maximum standardised uptake value (SUV<sub>max</sub>) of 18F-fluorodeoxyglucose positron emission tomography to improve the cost effectiveness of nimotuzumab (NTZ) in locoregionally advanced nasopharyngeal carcinoma (LA-NPC).</p><p><strong>Methods: </strong>Two hundred and forty-eigh patients with LA-NPC, who met the inclusion criteria, were recruited from January 2012 to June 2019. The survival differences and independent factors were assessed using the Kaplan-Meier method and by Cox proportional hazards regression analysis. A cost effectiveness analysis was performed.</p><p><strong>Results: </strong>The optimal cut-off value for SUV<sub>max</sub> was 12.92. Multivariable analysis indicated a prognostic significance of overall survival (OS) for the NTZ treatment (p = 0.023) and SUV<sub>max</sub> (p = 0.014). The exploratory subgroup survival analysis revealed that LA-NPC patients with SUV<sub>max</sub> > 12.92 treated with concurrent chemoradiotherapy (CCRT) and NTZ had a significantly improved 3-year OS compared to patients treated with CCRT alone (96.2 <i>vs</i> 73.2%, p = 0.047). Furthermore, the treatment cost for NTZ was $6,317.61. This incurred an additional cost of $274.68 for every 1% increase in OS.</p><p><strong>Conclusions: </strong>For patients with LA-NPC with SUV<sub>max</sub> > 12.92, the addition of NTZ to CCRT can improve OS and is cost effective.</p>","PeriodicalId":6890,"journal":{"name":"Acta Otorhinolaryngologica Italica","volume":"44 5","pages":"296-305"},"PeriodicalIF":2.1000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11556775/pdf/","citationCount":"0","resultStr":"{\"title\":\"Role of PET/CT in improving the cost effectiveness of nimotuzumab in nasopharyngeal carcinoma.\",\"authors\":\"Xiao-Bin Fu, Ting-Ting Li, Zhao-Dong Fei, Chuan-Ben Chen\",\"doi\":\"10.14639/0392-100X-N2827\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>This study aims to use the maximum standardised uptake value (SUV<sub>max</sub>) of 18F-fluorodeoxyglucose positron emission tomography to improve the cost effectiveness of nimotuzumab (NTZ) in locoregionally advanced nasopharyngeal carcinoma (LA-NPC).</p><p><strong>Methods: </strong>Two hundred and forty-eigh patients with LA-NPC, who met the inclusion criteria, were recruited from January 2012 to June 2019. The survival differences and independent factors were assessed using the Kaplan-Meier method and by Cox proportional hazards regression analysis. A cost effectiveness analysis was performed.</p><p><strong>Results: </strong>The optimal cut-off value for SUV<sub>max</sub> was 12.92. Multivariable analysis indicated a prognostic significance of overall survival (OS) for the NTZ treatment (p = 0.023) and SUV<sub>max</sub> (p = 0.014). The exploratory subgroup survival analysis revealed that LA-NPC patients with SUV<sub>max</sub> > 12.92 treated with concurrent chemoradiotherapy (CCRT) and NTZ had a significantly improved 3-year OS compared to patients treated with CCRT alone (96.2 <i>vs</i> 73.2%, p = 0.047). Furthermore, the treatment cost for NTZ was $6,317.61. This incurred an additional cost of $274.68 for every 1% increase in OS.</p><p><strong>Conclusions: </strong>For patients with LA-NPC with SUV<sub>max</sub> > 12.92, the addition of NTZ to CCRT can improve OS and is cost effective.</p>\",\"PeriodicalId\":6890,\"journal\":{\"name\":\"Acta Otorhinolaryngologica Italica\",\"volume\":\"44 5\",\"pages\":\"296-305\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11556775/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta Otorhinolaryngologica Italica\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.14639/0392-100X-N2827\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"OTORHINOLARYNGOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Otorhinolaryngologica Italica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.14639/0392-100X-N2827","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}
Role of PET/CT in improving the cost effectiveness of nimotuzumab in nasopharyngeal carcinoma.
Objective: This study aims to use the maximum standardised uptake value (SUVmax) of 18F-fluorodeoxyglucose positron emission tomography to improve the cost effectiveness of nimotuzumab (NTZ) in locoregionally advanced nasopharyngeal carcinoma (LA-NPC).
Methods: Two hundred and forty-eigh patients with LA-NPC, who met the inclusion criteria, were recruited from January 2012 to June 2019. The survival differences and independent factors were assessed using the Kaplan-Meier method and by Cox proportional hazards regression analysis. A cost effectiveness analysis was performed.
Results: The optimal cut-off value for SUVmax was 12.92. Multivariable analysis indicated a prognostic significance of overall survival (OS) for the NTZ treatment (p = 0.023) and SUVmax (p = 0.014). The exploratory subgroup survival analysis revealed that LA-NPC patients with SUVmax > 12.92 treated with concurrent chemoradiotherapy (CCRT) and NTZ had a significantly improved 3-year OS compared to patients treated with CCRT alone (96.2 vs 73.2%, p = 0.047). Furthermore, the treatment cost for NTZ was $6,317.61. This incurred an additional cost of $274.68 for every 1% increase in OS.
Conclusions: For patients with LA-NPC with SUVmax > 12.92, the addition of NTZ to CCRT can improve OS and is cost effective.
期刊介绍：
Acta Otorhinolaryngologica Italica first appeared as “Annali di Laringologia Otologia e Faringologia” and was founded in 1901 by Giulio Masini.
It is the official publication of the Italian Hospital Otology Association (A.O.O.I.) and, since 1976, also of the Società Italiana di Otorinolaringoiatria e Chirurgia Cervico-Facciale (S.I.O.Ch.C.-F.).
The journal publishes original articles (clinical trials, cohort studies, case-control studies, cross-sectional surveys, and diagnostic test assessments) of interest in the field of otorhinolaryngology as well as clinical techniques and technology (a short report of unique or original methods for surgical techniques, medical management or new devices or technology), editorials (including editorial guests – special contribution) and letters to the Editor-in-Chief.
Articles concerning science investigations and well prepared systematic reviews (including meta-analyses) on themes related to basic science, clinical otorhinolaryngology and head and neck surgery have high priority.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
